Navigating Regulatory Expectations for Demonstrating Potency of a Phase 1 Allogeneic Product
Time: 4:00 pm
day: Conference Day One
Details:
- FDA recommendations and approaches for potency/functional assessments of investigational cell therapy products
- Differences in FDA and EMA regulatory expectations
- Considerations for surrogate assays and cell-based potency/functional assay development
